We are live on
!
Find out more
Handelsbanken Fonder Portfolio holdings
AUM
$35.1B
1-Year Est. Return
47.76%
This Fund
S&P 500
This Quarter
Est. Return
-15%
1 Year Est. Return
+47.76%
3 Year Est. Return
+137.96%
5 Year Est. Return
+170.36%
10 Year Est. Return
+934.7%
AUM
$4.96B
AUM Growth
-$360M
(-6.8%)
Cap. Flow
+$564M
Cap. Flow
% of AUM
11.37%
Top 10 Holdings %
Top 10 Hldgs %
25.68%
Holding
191
New
9
Increased
107
Reduced
41
Closed
24
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alibaba
BABA
|
+$53M |
| 2 |
Abbott
ABT
|
+$38.6M |
| 3 |
Pool Corp
POOL
|
+$37M |
| 4 |
NetEase
NTES
|
+$35.6M |
| 5 |
Service Corp International
SCI
|
+$29M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$48.5M |
| 2 |
Bank OZK
OZK
|
+$34.4M |
| 3 |
Meta Platforms (Facebook)
META
|
+$22.5M |
| 4 |
XPO
XPO
|
+$19.4M |
| 5 |
Owens Corning
OC
|
+$12.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 19.07% |
| 2 | Healthcare | 18.08% |
| 3 | Industrials | 14.01% |
| 4 | Financials | 13.7% |
| 5 | Technology | 13.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CNR
151
DELISTED
Cornerstone Building Brands, Inc.
CNR
| $2.93M | 0.06% |
404,143
-395,857
| -49% | -$4.75M |
|
152
Sarepta Therapeutics
SRPT
$1.94B
| $2.89M | 0.06% |
26,500
-6,000
| -18% | -$750K |
|
|
ARQL
153
DELISTED
Arqule Inc
ARQL
| $2.77M | 0.06% |
1,000,000
| – | – |
|
|
MYOK
154
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $2.59M | 0.05% |
53,000
-10,000
| -16% | -$550K |
|
|
JKS
155
JinkoSolar
JKS
$860M
| $2.34M | 0.05% |
236,536
+79,692
| +51% | +$787K |
|
|
FOMX
156
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $2.3M | 0.05% |
640,000
| – | – |
|
157
Nektar Therapeutics
NKTR
$2.57B
| $2.1M | 0.04% |
4,269
+902
| +27% | +$544K |
|
158
Minerva Neurosciences
NERV
$187M
| $1.38M | 0.03% |
25,625
| – | – |
|
|
SGMO
159
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $1.09M | 0.02% |
95,000
-450,000
| -83% | -$5.59M |
|
160
Infosys
INFY
$49.7B
| $1.08M | 0.02% |
+113,200
| New | +$1.08M |
|
161
Yum China
YUMC
$16.4B
| $1.01M | 0.02% |
30,000
-5,000
| -14% | -$172K |
|
|
JOYY
162
JOYY Inc
JOYY
$3.74B
| $880K | 0.02% |
14,700
| – | – |
|
163
HDFC Bank
HDB
$119B
| $829K | 0.02% |
+32,000
| New | +$756K |
|
164
Digimarc Corp
DMRC
$167M
| $725K | 0.01% |
50,000
+36,300
| +265% | +$796K |
|
165
Teva Pharmaceuticals
TEVA
$42.8B
| $694K | 0.01% |
45,000
+22,500
| +100% | +$461K |
|
|
QIWI
166
DELISTED
QIWI PLC
QIWI
| $566K | 0.01% |
+40,000
| New | +$539K |
|
167
Robert Half
RHI
$4.25B
| $276K | 0.01% |
+4,818
| New | +$296K |
|
168
Accenture
ACN
$110B
| – | – |
-2,225
| Closed | -$379K |
|
169
AnaptysBio
ANAB
$1.69B
| – | – |
-16,000
| Closed | -$1.6M |
|
170
Badger Meter
BMI
$3.91B
| – | – |
-16,419
| Closed | -$869K |
|
171
Bristol-Myers Squibb
BMY
$130B
| – | – |
-51,060
| Closed | -$3.17M |
|
|
BPMC
172
DELISTED
Blueprint Medicines
BPMC
| – | – |
-19,000
| Closed | -$1.48M |
|
173
Brady Corp
BRC
$4.48B
| – | – |
-4,707
| Closed | -$206K |
|
174
Cigna
CI
$73.3B
| – | – |
-2,568
| Closed | -$535K |
|
175
Deere & Co
DE
$167B
| – | – |
-7,000
| Closed | -$1.05M |
|
Similar funds
VIA
Handelsbanken Fonder's Q4 2018 Portfolio in Review
As of Q4 2018, Handelsbanken Fonder held 191 positions worth $4.96B, down 6.8% from $5.32B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Handelsbanken Fonder deployed $564M of net new capital in Q4 2018, opening 9 new positions and adding to 107 existing holdings. Its largest new stake was WW International: 238,281 shares worth $9.19M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 19% of assets, up from 18% a quarter earlier, followed by Healthcare and Industrials.
On the sell side, the largest reduction was Meta Platforms (Facebook), an estimated $22.5M trimmed.
- Handelsbanken Fonder's largest Q4 2018 buy was WW International: 238,281 shares worth $9.19M.
- Handelsbanken Fonder added most to Alibaba in Q4 2018, an estimated $53M increase.
- Handelsbanken Fonder's biggest Q4 2018 reduction was Meta Platforms (Facebook), cutting an estimated $22.5M.
- Handelsbanken Fonder fully exited Celgene Corp in Q4 2018, selling an estimated $48.5M.
- Handelsbanken Fonder's ten largest holdings make up 26% of its $4.96B portfolio in Q4 2018.
- Handelsbanken Fonder opened 9 new positions and closed 24 in Q4 2018.
- Handelsbanken Fonder's portfolio value fell 6.8% quarter-over-quarter to $4.96B.
Based on Handelsbanken Fonder's 13F filing for Q4 2018, filed 31 Jan 2019.